Lymphoma

• 1. Introduction

  ›

  Lymphoma is not one disease but a whole family of blood and lymph tumors, each arising from a single cell type: the lymphocyte, a white blood cell that normally defends the body against infection. In 2012, lymphomas developed in 566,000 people worldwide and caused 305,000 deaths. They make up 3-4% of all cancers globally, and among children they rank as the third-most-common cancer. Yet within that grim statistic lives a paradox that will recur throughout this story: some of the fastest-growing, most aggressive lymphomas are also the most curable, while certain slow-moving forms resist every attempt at a permanent cure.

  The name itself comes from Latin and Greek roots. "Lympha" meant water, and "-oma" described a morbid growth or tumor. Thomas Hodgkin gave the disease its first formal description in 1832, writing about a form that would carry his name ever after. What he could not have known was that dozens of distinct subtypes would eventually be catalogued, each with its own biology, its own prognosis, and its own demands on treatment.

  The questions this documentary will pursue are deceptively simple. What makes one lymphoma sluggish and another lethal within days? How did medicine learn to tell them apart? And what does it mean when a doctor says a cancer is curable yet technically cannot be cured?

• 2. Two Families, Many Faces

  ›

  Ninety percent of all lymphoma cases fall into a single broad category: non-Hodgkin lymphoma. The remaining ten percent are Hodgkin lymphoma. That split matters because the two groups differ not just in frequency but in the very architecture of their cells and in how the body responds to them.

  Hodgkin lymphoma is defined by a distinctive cellular signature: the Reed-Sternberg cell. These abnormal cells, mingled with surrounding inflammation, set Hodgkin disease apart from every other lymphoma on a microscope slide. The most common variant, nodular sclerosis Hodgkin lymphoma, tends to arise in the mediastinum or cervical lymph nodes and most often strikes young adults. Mixed cellularity Hodgkin lymphoma, the second-most-common form, is more frequently diagnosed at advanced stages and involves Epstein-Barr virus in roughly 70% of cases.

  Non-Hodgkin lymphomas, by contrast, are a vast and diverse collection. Diffuse large B-cell lymphoma accounts for 40-50% of adult lymphoma cases. Follicular lymphoma accounts for about 40% of adult cases and is strongly associated with a chromosomal rearrangement known as t(14;18), which causes overexpression of a protein called Bcl-2. At the other end of the spectrum, Burkitt lymphoma represents less than 1% of cases in the United States; it is endemic in Africa and more common in people who are immunocompromised.

  Myosis fungoides and Sézary syndrome occupy a different territory altogether: the skin. Mycosis fungoides is the most common cutaneous lymphoid malignancy, with a five-year survival rate of 75%. Its more aggressive variant, Sézary disease, involves both skin erythema and peripheral blood.

• 3. Reading the Warning Signs

  ›

  Swollen lymph nodes are the primary presentation in lymphoma, and they share a quality that can mislead patients and delay diagnosis: they are generally painless. A lump that does not hurt is easy to dismiss.

  Beyond that hallmark, physicians look for a cluster known as B symptoms. These are fever, night sweats, and unintentional loss of at least 10% of body weight in the last six months. The sweats are most common at night, and in the Ann Arbor staging system their presence earns the designation "B"; their absence earns "A." A persistent fever of 38 degrees Celsius or more also qualifies.

  Other symptoms shade into the nonspecific: fatigue, itching, loss of appetite, respiratory distress. Anemia and increased susceptibility to infections can appear as the disease disrupts normal blood production. None of these symptoms point exclusively to lymphoma, which is why the source notes that evaluation should be undertaken when symptoms persist, not simply when they appear once.

  Lymphoma can also spread to the central nervous system, settling around the brain in the meninges in a complication called lymphomatous meningitis. When cancer does spread, the organs it most often reaches are the lungs, liver, and brain. In some non-Hodgkin lymphomas, the tumor cells produce such large amounts of protein that the blood itself thickens; in those cases, a procedure called plasmapheresis is used to remove the excess protein from circulation.

• 4. Staging and Classification

  ›

  Once lymphoma is confirmed by a lymph-node biopsy, the next task is determining how far it has traveled. Staging uses a scale from I to IV. Stage I means the cancer is confined within a single lymph node group; Stage II indicates involvement in two or more groups; Stage III reflects spread to lymph node groups on both sides of the diaphragm; and Stage IV signals that the cancer has moved into tissue outside the lymphatic system entirely.

  The Ann Arbor staging system attaches letter suffixes to capture specific organ involvement. S marks the spleen; H marks the liver; E denotes extra-lymphatic spread. Age and physical condition are also factored into prognosis: people who are elderly or unable to care for themselves face a worse outlook than others at the same stage.

  For imaging, PET scanning is preferred for fluorodeoxyglucose-avid lymphomas such as Hodgkin lymphoma, and can even replace bone marrow biopsy in those cases. CT scanning is recommended for staging other lymphoma types.

  The classification of lymphoma has gone through several iterations. The Working Formulation of 1982 organized non-Hodgkin lymphomas into four grades based purely on cell size and shape, with no information about cell surface markers or genetics. By 2004 it was considered obsolete. The Revised European-American Lymphoma classification of 1994 introduced immunophenotypic and genetic features. The World Health Organization built on that foundation in a classification first published in 2001 and updated in 2008, 2017, and 2022, which groups lymphomas by the normal cell type the tumor most closely resembles.

• 5. The Paradox of Aggression

  ›

  Burkitt lymphoma can double in size within days. That rate of growth sounds like a death sentence, yet Burkitt lymphoma is highly responsive to treatment. The same pattern holds across many aggressive lymphomas: faster growth often means greater sensitivity to chemotherapy, because the drugs target dividing cells.

  For high-grade lymphomas, treatment typically involves aggressive chemotherapy regimens such as CHOP or R-CHOP. Many patients are cured with first-line chemotherapy. Most relapses occur within the first two years, and the risk of relapse drops significantly after that window. Patients who do relapse can pursue high-dose chemotherapy followed by autologous stem cell transplantation, a proven approach for that situation.

  Four chimeric antigen receptor T-cell therapies have received FDA approval for non-Hodgkin lymphoma. Lisocabtagene maraleucel is approved for relapsed or refractory large B-cell lymphoma after two failed systemic treatments. Axicabtagene ciloleucel and tisagenlecleucel are approved for large B-cell lymphoma. Brexucabtagene autoleucel is approved for mantle cell lymphoma. All four come with certification requirements and other restrictions.

  Hodgkin lymphoma, when localized, is typically treated with radiotherapy alone. Advanced Hodgkin disease requires systemic chemotherapy, sometimes combined with radiotherapy. The ABVD regimen is commonly used in the United States. BEACOPP is another option, though it carries more toxicity. Patients who relapse after ABVD can often still be salvaged by stem cell transplantation.

• 6. Living With the Slow Ones

  ›

  Follicular lymphoma accounts for roughly 40% of adult lymphoma cases, and many of its patients will live near-normal lifespans. That outcome sounds reassuring until you learn the qualifier: the disease is technically incurable in most cases. It simply grows so slowly that treatment is often withheld entirely.

  Watchful waiting, which some patients have called "watch and worry," is a deliberate choice to monitor the disease rather than treat it, because early treatment carries its own risks and harms without offering a cure. Some centers prefer offering single-agent rituximab instead, given the significant distress and anxiety that watchful waiting imposes on some patients. The decision turns on individual tolerance of uncertainty as much as on clinical criteria.

  When a low-grade lymphoma does become symptomatic, radiotherapy or chemotherapy can alleviate painful lymphadenopathy, even if they cannot eliminate the disease permanently. B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma carry a five-year survival rate of 50% and occur most often in older adults; they usually involve the lymph nodes, bone marrow, and spleen and follow an indolent course.

  Palliative care is recommended alongside curative treatments by multiple national cancer guidelines. For children with lymphoma, palliative care helps both patients and families manage the physical and emotional weight of the disease. It is considered especially important for people undergoing bone marrow transplants, where the side effects of the procedure itself can be as demanding as the cancer.

• 7. Risk, Biology, and History

  ›

  Risk factors for the two main branches of lymphoma differ in telling ways. For Hodgkin lymphoma, the established risk factors are infection with Epstein-Barr virus and a family history of the disease. For common non-Hodgkin lymphomas, the list is longer: autoimmune diseases, HIV/AIDS infection, infection with human T-lymphotropic virus, immunosuppressant medications, and certain pesticides. Eating large amounts of red meat and tobacco smoking may also increase the risk.

  The connection to immune system compromise runs through much of the epidemiology. Because the lymphatic system is integral to immune defense, people with weakened immunity, whether from HIV or from medications, show higher rates of lymphoma. Primary central nervous system lymphoma occurs most often in immunocompromised patients, particularly those with AIDS, though it can appear in immunocompetent people as well.

  Lymphomas occur more often in the developed world than in the developing world. In the United States, they represent 5.3% of all cancers excluding common skin cancers, and 55.6% of all blood cancers. Hodgkin lymphoma alone accounts for less than 1% of all cancer cases in the country.

  Thomas Hodgkin published his original description in 1832. The disease he described bore his name from that point forward, and the decades that followed produced a cascade of new descriptions as pathologists separated lymphoma into ever-finer categories. The five-year survival rate for all Hodgkin lymphoma subtypes in the United States now stands at 89%. For non-Hodgkin lymphomas it is 74%, with outcomes varying sharply by subtype and stage.